filmov
tv
The $1 Billion Obesity Pill That’s NOT a GLP 1

Показать описание
Novo Nordisk's Billion-Dollar Obesity Drugs, Semaglutide Study, and GLP-1 Impact
In this episode of Downsized News, hosts Laraine and Christopher Durham discuss the latest developments in the GLP-1 medications and obesity treatment space. Key topics include Novo Nordisk's billion-dollar deal with Lexicon Pharmaceuticals for the new non-GLP-1 obesity pill LX 9851 and its potential game-changing impact. They also talk about a new study on the Semaglutide pill showing it can reduce heart attack and stroke risks by 14% in type 2 diabetes patients. The episode reveals how GLP-1s are driving up drug costs and contributing to the decline of weight loss giants like Medifast. Other highlights include the rise of oral GLP-1 drugs, a partnership between Collective Health and Noom to make these medications more accessible, and data from Deloitte showing the massive impact of GLP-1 drugs on the pharmaceutical industry. The hosts emphasize the importance of consulting healthcare professionals and being cautious about the high costs of these medications. They end by highlighting their store and thanking their members for their support.
JOIN CLUB DOWNSIZED: / @thedownsized
00:00 Introduction and Overview
01:19 Novo Nordisk's Billion Dollar Deal
04:50 The SOUL Trial: Oral Semaglutide
07:45 Impact of GLP-1 Drugs on Drug Costs
11:51 Medifast's Struggles in the GLP-1 Era
15:17 Rani Therapeutics' New Oral Obesity Medication
17:56 Collective Health and Noom Partnership
20:00 Deloitte Report on GLP-1 Drugs
24:23 Conclusion and Sign Off
In this episode of Downsized News, hosts Laraine and Christopher Durham discuss the latest developments in the GLP-1 medications and obesity treatment space. Key topics include Novo Nordisk's billion-dollar deal with Lexicon Pharmaceuticals for the new non-GLP-1 obesity pill LX 9851 and its potential game-changing impact. They also talk about a new study on the Semaglutide pill showing it can reduce heart attack and stroke risks by 14% in type 2 diabetes patients. The episode reveals how GLP-1s are driving up drug costs and contributing to the decline of weight loss giants like Medifast. Other highlights include the rise of oral GLP-1 drugs, a partnership between Collective Health and Noom to make these medications more accessible, and data from Deloitte showing the massive impact of GLP-1 drugs on the pharmaceutical industry. The hosts emphasize the importance of consulting healthcare professionals and being cautious about the high costs of these medications. They end by highlighting their store and thanking their members for their support.
JOIN CLUB DOWNSIZED: / @thedownsized
00:00 Introduction and Overview
01:19 Novo Nordisk's Billion Dollar Deal
04:50 The SOUL Trial: Oral Semaglutide
07:45 Impact of GLP-1 Drugs on Drug Costs
11:51 Medifast's Struggles in the GLP-1 Era
15:17 Rani Therapeutics' New Oral Obesity Medication
17:56 Collective Health and Noom Partnership
20:00 Deloitte Report on GLP-1 Drugs
24:23 Conclusion and Sign Off
Комментарии